Merck & Co.
ASCO 2016 was Merck & Co.’s opportunity to present key data highlighting their recently FDA-approved product, Keytruda, at the premier educational and research trade show for oncology specialists. This promising treatment of melanoma and non-small cell lung cancer (NSCLC) provided Merck an additional opportunity to reinforce their position as a leader in the therapeutic area. Merck Oncology’s exhibit and marketing team in partnership with the GES program account team, along with GES trade show and GES ExpoServices, executed a highly successful attendee experience. The educational tools and interactive pipeline data highlighted the current treatment approvals as well as the drug’s potential for improved patient outcomes, extending audience visits for more than 2x the average length of time.
Further, the launch of Keytruda coincided with the selection of GES as Merck’s partner for management of their overall global exhibit program and the execution of a 5+ year master services agreement through 2020.